{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Vehicle+for+Cyclosporine%29",
    "query": {
      "intervention": "Placebo (Vehicle for Cyclosporine)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T16:40:45.994Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04734197",
      "title": "A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolic Acid 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolic Acid 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Betamethasone Sodium Phosphate 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine 0.05% Ophthalmic Emulsion",
          "type": "DRUG"
        },
        {
          "name": "Lifitegrast 5% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Surface Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 349,
      "start_date": "2021-01-11",
      "completion_date": "2022-03-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-10-06T16:40:45.994Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Azusa, California • Hemet, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04734197"
    },
    {
      "nct_id": "NCT00884585",
      "title": "Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Cyclosporine Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine 0.010%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2009-05",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2012-11-05",
      "last_synced_at": "2026-10-06T16:40:45.994Z",
      "location_count": 1,
      "location_summary": "Bakersfield, California",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00884585"
    },
    {
      "nct_id": "NCT00833495",
      "title": "Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Prednisolone Acetate 0.12% (Pred Mild®)",
          "type": "DRUG"
        },
        {
          "name": "FOV1101-00",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 1% (Pred Forte®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fovea Pharmaceuticals SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2009-01",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-09",
      "last_synced_at": "2026-10-06T16:40:45.994Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00833495"
    },
    {
      "nct_id": "NCT05136170",
      "title": "Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Cenegermin",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2022-01-27",
      "completion_date": "2023-05-24",
      "has_results": true,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-10-06T16:40:45.994Z",
      "location_count": 7,
      "location_summary": "Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Garden City",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136170"
    },
    {
      "nct_id": "NCT00739349",
      "title": "NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "NOVA22007 ''Cyclosporine''",
          "type": "DRUG"
        },
        {
          "name": "vehicle/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen SAS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2008-08",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2016-06-06",
      "last_synced_at": "2026-10-06T16:40:45.994Z",
      "location_count": 1,
      "location_summary": "Lewiston, Maine",
      "locations": [
        {
          "city": "Lewiston",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00739349"
    },
    {
      "nct_id": "NCT02617667",
      "title": "CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "Cyclosporine A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novaliq GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 207,
      "start_date": "2016-01",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2019-11-06",
      "last_synced_at": "2026-10-06T16:40:45.994Z",
      "location_count": 4,
      "location_summary": "Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Lewiston",
          "state": "Maine"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Quincy",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02617667"
    },
    {
      "nct_id": "NCT00991458",
      "title": "Study of Cyclosporine in Post-LASIK Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Laser In Situ Keratomileusis"
      ],
      "interventions": [
        {
          "name": "Cyclosporine 0.010% eye drops",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine 0.005% eye drops",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Vehicle for Cyclosporine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 621,
      "start_date": "2009-10",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2013-07-11",
      "last_synced_at": "2026-10-06T16:40:45.994Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00991458"
    },
    {
      "nct_id": "NCT04362670",
      "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OTX-CSI",
          "type": "DRUG"
        },
        {
          "name": "Placebo Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2020-04-23",
      "completion_date": "2021-08-11",
      "has_results": true,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-10-06T16:40:45.994Z",
      "location_count": 15,
      "location_summary": "Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04362670"
    }
  ]
}